Rhenman & Partners Asset Management Ab Mersana Therapeutics, Inc. Transaction History

Rhenman & Partners Asset Management Ab

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$1.06 - $3.91 $400,998 - $1.48 Million	378,300 Added 1743.32%	400,000 $508,000
Q3 2023 Nov 09, 2023	SELL	$1.06 - $3.91 $400,998 - $1.48 Million	-378,300 Reduced 94.58%	21,700 $27,000
Q2 2023 Aug 11, 2023	BUY	$3.08 - $9.55 $154,000 - $477,500	50,000 Added 14.29%	400,000 $1.32 Million
Q1 2023 May 11, 2023	SELL	$4.0 - $7.02 $200,000 - $351,000	-50,000 Reduced 12.5%	350,000 $1.44 Million
Q4 2022 Feb 13, 2023	BUY	$5.65 - $7.86 $2.26 Million - $3.14 Million	400,000 New	400,000 $2.34 Million

125

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $52.5M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.